Elise Sverre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elise Sverre has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- John Munkhaugen
Department of Medicine, Drammen Hospital, Vestre Viken Trust
6 shared publications - Nils Tore Vethe
Department of Pharmacology Oslo University Hospital Oslo Norway
6 shared publications John Munkhaugen
5 shared publicationsJoep Perk
Faculty of Health Sciences Linnaeus University Kalmar Sweden
4 shared publicationsKari Peersen
Department of Cardiology Vestfold Hospital Trust Tønsberg Norway
4 shared publications- Oscar Kristiansen
Department of Medicine Drammen Hospital, Vestre Viken Hospital Trust Drammen Norway
4 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Elsevier in Atherosclerosis
- Vol. 423
Sex-specific clinical and psychosocial characteristics among individuals with familial hypercholesterolemia reporting side-effects of lipid-lowering therapy
- 4 November 2026
- Published by Elsevier in Atherosclerosis
- Vol. 423
Open AccessSex-specific clinical and psychosocial characteristics among individuals with familial hypercholesterolemia reporting side-effects of lipid-lowering therapy
- Open Access
- 11 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Beta-blocker therapy and physical activity after myocardial infarction: a preplanned sub-study of the BETAMI trial
Aims: To investigate the effect of long-term beta-blocker therapy on physical activity (PA) level after myocardial infarction (MI) in patients without heart failure. Methods and results: The BETAMI trial randomized patients hospitalized with a MI without heart failure (LVEF ≥40%) to beta-blocker or no beta-blocker. In this preplanned sub-study, PA level was assessed by guideline-recommended PA level (≥30 min moderate activity ≥5 days/week) or not and self-reported hours/week with light to moderate and vigorous PA. Between-group differences in PA from baseline before randomization to 18-months were estimated by linear mixed models. Exploratory analysis assessed treatment effects on a composite of all-cause mortality and major adverse cardiovascular events using a Cox proportional hazards model. Of the 2867 randomized patients, 2185 (76%) responded to the PA questions and were included in this analysis. Mean age was 62.5 (SD 10.1) years, and 20.6% were women. No differences in guideline-recommended PA level or mean hours of light to moderate and vigorous PA were reported between the beta-blocker and non-beta-blocker group at baseline or during 18-month follow-up. At 12-month follow-up, 37.0% in the beta-blocker group and 36.7% in the no beta-blocker group reported guideline-recommended PA level (OR 0.97, 95% CI 0.69–1.37). Exploratory, hypothesis-generating analyses did not demonstrate a statistically significant interaction (P for interaction = 0.06) between treatment assignment and baseline PA level for recurrent clinical events. Conclusion: Beta-blocker therapy did not result in a change in PA level in post-MI patients without heart failure during the 18-month follow-up. Registration: ClinicalTrials.gov. URL: https://clinicaltrials.gov/search?term==NCT03646357. Unique identifier: NCT03646357, registered on 23 August 2018.
- 11 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Open AccessBeta-blocker therapy and physical activity after myocardial infarction: a preplanned sub-study of the BETAMI trial
Aims: To investigate the effect of long-term beta-blocker therapy on physical activity (PA) level after myocardial infarction (MI) in patients without heart failure. Methods and results: The BETAMI trial randomized patients hospitalized with a MI without heart failure (LVEF ≥40%) to beta-blocker or no beta-blocker. In this preplanned sub-study, PA level was assessed by guideline-recommended PA level (≥30 min moderate activity ≥5 days/week) or not and self-reported hours/week with light to moderate and vigorous PA. Between-group differences in PA from baseline before randomization to 18-months were estimated by linear mixed models. Exploratory analysis assessed treatment effects on a composite of all-cause mortality and major adverse cardiovascular events using a Cox proportional hazards model. Of the 2867 randomized patients, 2185 (76%) responded to the PA questions and were included in this analysis. Mean age was 62.5 (SD 10.1) years, and 20.6% were women. No differences in guideline-recommended PA level or mean hours of light to moderate and vigorous PA were reported between the beta-blocker and non-beta-blocker group at baseline or during 18-month follow-up. At 12-month follow-up, 37.0% in the beta-blocker group and 36.7% in the no beta-blocker group reported guideline-recommended PA level (OR 0.97, 95% CI 0.69–1.37). Exploratory, hypothesis-generating analyses did not demonstrate a statistically significant interaction (P for interaction = 0.06) between treatment assignment and baseline PA level for recurrent clinical events. Conclusion: Beta-blocker therapy did not result in a change in PA level in post-MI patients without heart failure during the 18-month follow-up. Registration: ClinicalTrials.gov. URL: https://clinicaltrials.gov/search?term==NCT03646357. Unique identifier: NCT03646357, registered on 23 August 2018.
- Open Access
- 23 October 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (10) , e70025
Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease
Statin‐associated muscle symptoms are frequently reported and often lead to discontinuation of statin therapy with an increased risk of cardiovascular events. In vitro studies suggest that statin‐mediated inhibition of the mevalonate pathway leads to muscle cell toxicity. We aimed to determine the relationship between mevalonate, LDL‐cholesterol, and atorvastatin metabolites in patients with coronary heart disease and self‐perceived muscle side effects. Furthermore, we assessed the correlation between mevalonate in blood and muscle and the relationship to statin intolerance due to muscle symptoms. We used blood plasma from a randomized crossover trial (n = 70) and muscle biopsies and plasma from a subgroup in a subsequent open intervention study (n = 26). Both studies tested atorvastatin 40 mg/day. Seven patients did not tolerate ≥3 statins throughout the follow‐up and were classified as statin‐intolerant. Mevalonate in blood plasma decreased during atorvastatin treatment (median difference −38%, range −77% to 43%, p < 0.001), whereas mevalonate in muscle tissue was not lowered (0.05%, range −47% to 145%). Mevalonate correlated poorly with LDL‐cholesterol and atorvastatin metabolites (Spearman's rho −0.28 to 0.10). The statin‐intolerant patients had a smaller reduction in circulating mevalonate compared with the tolerant patients; median difference −8.1 (−22 to 3.5) nmol/L versus −25 (−93 to 12) nmol/L, p = 0.028. A similar observation was made for LDL‐cholesterol. Cutoffs based on these biomarkers classified >50% correctly as tolerant. Inhibition of the mevalonate pathway does not appear to be the mechanism underlying statin intolerance in the present study. Further studies of mevalonate as a biomarker for statin tolerance are needed to clarify the potential.
- 23 October 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (10) , e70025
Open AccessMevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease
Statin‐associated muscle symptoms are frequently reported and often lead to discontinuation of statin therapy with an increased risk of cardiovascular events. In vitro studies suggest that statin‐mediated inhibition of the mevalonate pathway leads to muscle cell toxicity. We aimed to determine the relationship between mevalonate, LDL‐cholesterol, and atorvastatin metabolites in patients with coronary heart disease and self‐perceived muscle side effects. Furthermore, we assessed the correlation between mevalonate in blood and muscle and the relationship to statin intolerance due to muscle symptoms. We used blood plasma from a randomized crossover trial (n = 70) and muscle biopsies and plasma from a subgroup in a subsequent open intervention study (n = 26). Both studies tested atorvastatin 40 mg/day. Seven patients did not tolerate ≥3 statins throughout the follow‐up and were classified as statin‐intolerant. Mevalonate in blood plasma decreased during atorvastatin treatment (median difference −38%, range −77% to 43%, p < 0.001), whereas mevalonate in muscle tissue was not lowered (0.05%, range −47% to 145%). Mevalonate correlated poorly with LDL‐cholesterol and atorvastatin metabolites (Spearman's rho −0.28 to 0.10). The statin‐intolerant patients had a smaller reduction in circulating mevalonate compared with the tolerant patients; median difference −8.1 (−22 to 3.5) nmol/L versus −25 (−93 to 12) nmol/L, p = 0.028. A similar observation was made for LDL‐cholesterol. Cutoffs based on these biomarkers classified >50% correctly as tolerant. Inhibition of the mevalonate pathway does not appear to be the mechanism underlying statin intolerance in the present study. Further studies of mevalonate as a biomarker for statin tolerance are needed to clarify the potential.
- 9 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 10 (4) , 307-315
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
Objective methods to determine statin adherence are requested to improve lipid management. We have recently established a method to detect reduced adherence to atorvastatin therapy with cut‐off values based on the sum of atorvastatin and its major metabolites in the blood. We aimed to validate this method in patients with and without cardiovascular disease, and optimize previous cut-off values. The pharmacokinetic study included 60 participants treated with atorvastatin 20 mg (N = 20), 40 mg (N = 20), and 80 mg (N = 20). Atorvastatin was then stopped and blood samples collected from day zero to day four. Quantification of the parent drug and its metabolites in blood plasma was performed with a liquid chromatography-tandem mass spectrometry assay. The cut-off values for reduced adherence were validated and optimized by calculating diagnostic sensitivity and specificity. Our candidate cut-off value of dose-normalized six-component sum of atorvastatin plus metabolites <0.10 nM/mg provided a sensitivity of 97% and a specificity of 93% for detecting ≥2 omitted doses. An optimized cut-off <0.062 nM/mg provided a sensitivity of 90% and a specificity of 100%. An alternative simplified two-component metabolite sum with a cut-off value <0.05 nM/mg provided a sensitivity of 98% and a specificity of 76%. An optimized cut-off <0.02 nM/mg provided a sensitivity of 97% and a specificity of 98%. This validation study confirms that our direct method discriminates reduced adherence from adherence to atorvastatin therapy with high diagnostic accuracy. The method may improve lipid management in clinical practice and serve as a useful tool in future studies.
- 9 January 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 10 (4) , 307-315
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
Objective methods to determine statin adherence are requested to improve lipid management. We have recently established a method to detect reduced adherence to atorvastatin therapy with cut‐off values based on the sum of atorvastatin and its major metabolites in the blood. We aimed to validate this method in patients with and without cardiovascular disease, and optimize previous cut-off values. The pharmacokinetic study included 60 participants treated with atorvastatin 20 mg (N = 20), 40 mg (N = 20), and 80 mg (N = 20). Atorvastatin was then stopped and blood samples collected from day zero to day four. Quantification of the parent drug and its metabolites in blood plasma was performed with a liquid chromatography-tandem mass spectrometry assay. The cut-off values for reduced adherence were validated and optimized by calculating diagnostic sensitivity and specificity. Our candidate cut-off value of dose-normalized six-component sum of atorvastatin plus metabolites <0.10 nM/mg provided a sensitivity of 97% and a specificity of 93% for detecting ≥2 omitted doses. An optimized cut-off <0.062 nM/mg provided a sensitivity of 90% and a specificity of 100%. An alternative simplified two-component metabolite sum with a cut-off value <0.05 nM/mg provided a sensitivity of 98% and a specificity of 76%. An optimized cut-off <0.02 nM/mg provided a sensitivity of 97% and a specificity of 98%. This validation study confirms that our direct method discriminates reduced adherence from adherence to atorvastatin therapy with high diagnostic accuracy. The method may improve lipid management in clinical practice and serve as a useful tool in future studies.
- Open Access
- 26 April 2023
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 11 (3) , e01089
Plasma concentration of atorvastatin metabolites correlates with low‐density lipoprotein cholesterol reduction in patients with coronary heart disease
In this exploratory study from a randomized double‐blinded crossover trial including 70 patients with coronary heart disease and self‐perceived muscular side effects of statins, we aimed to determine the relationship between low‐density lipoprotein cholesterol (LDL‐C) reduction and atorvastatin metabolite plasma concentrations. All patients underwent a 7 weeks treatment period with atorvastatin 40 mg/day and a 7 weeks placebo period in random order. Nonlinear regression with a three‐parameter equation explored the relationship between percentage LDL‐C reduction (statin vs. placebo) and the pharmacokinetic variables. Mean LDL‐C reduction was 49% (range 12% to 71%). The sum of 4‐OH‐atorvastatin acid and lactone correlated moderately with the LDL‐C response (Spearman ρ 0.27, 95% confidence interval [CI]: 0.03 to 0.48). Accordingly, nonlinear regression showed R2 of 0.14 (95% CI: 0.03 to 0.37, R2 adjusted equaled 0.11). Even a perfect underlying correlation of 1.0 showed R2 = 0.32 by simulation, using historical intra‐individual LDL‐C variation (8.5%). The 90% inhibitory concentration was 2.1 nmol/L, and the 4‐OH‐metabolite sum exceeded this threshold in 34% of the patients. In conclusion, trough plasma concentrations of 4‐OH‐atorvastatin metabolites correlated moderately to the LDL‐C reduction. A plateau LDL‐C response was observed above a pharmacokinetic threshold, below which the response was highly variable. The usefulness of monitoring concentrations of atorvastatin metabolites to optimize the individual dosage have limitations, but its supportive potential may be pursued in relevant patient subsets to achieve adequate efficacy at the lowest possible dose. The results add knowledge to the overall understanding of the variable LDL‐C response mediated by atorvastatin.
- 26 April 2023
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 11 (3) , e01089
Open AccessPlasma concentration of atorvastatin metabolites correlates with low‐density lipoprotein cholesterol reduction in patients with coronary heart disease
In this exploratory study from a randomized double‐blinded crossover trial including 70 patients with coronary heart disease and self‐perceived muscular side effects of statins, we aimed to determine the relationship between low‐density lipoprotein cholesterol (LDL‐C) reduction and atorvastatin metabolite plasma concentrations. All patients underwent a 7 weeks treatment period with atorvastatin 40 mg/day and a 7 weeks placebo period in random order. Nonlinear regression with a three‐parameter equation explored the relationship between percentage LDL‐C reduction (statin vs. placebo) and the pharmacokinetic variables. Mean LDL‐C reduction was 49% (range 12% to 71%). The sum of 4‐OH‐atorvastatin acid and lactone correlated moderately with the LDL‐C response (Spearman ρ 0.27, 95% confidence interval [CI]: 0.03 to 0.48). Accordingly, nonlinear regression showed R2 of 0.14 (95% CI: 0.03 to 0.37, R2 adjusted equaled 0.11). Even a perfect underlying correlation of 1.0 showed R2 = 0.32 by simulation, using historical intra‐individual LDL‐C variation (8.5%). The 90% inhibitory concentration was 2.1 nmol/L, and the 4‐OH‐metabolite sum exceeded this threshold in 34% of the patients. In conclusion, trough plasma concentrations of 4‐OH‐atorvastatin metabolites correlated moderately to the LDL‐C reduction. A plateau LDL‐C response was observed above a pharmacokinetic threshold, below which the response was highly variable. The usefulness of monitoring concentrations of atorvastatin metabolites to optimize the individual dosage have limitations, but its supportive potential may be pursued in relevant patient subsets to achieve adequate efficacy at the lowest possible dose. The results add knowledge to the overall understanding of the variable LDL‐C response mediated by atorvastatin.
- Open Access
- 21 November 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (17)
Personalised cardiovascular disease prevention in the new guidelines
21.11.2022: Kronikk - I de nye europeiske retningslinjene for forebygging av hjerte- og karsykdommer introduseres en trinnvis tiltaksmodell.
- 21 November 2022
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 142 (17)
Open AccessPersonalised cardiovascular disease prevention in the new guidelines
21.11.2022: Kronikk - I de nye europeiske retningslinjene for forebygging av hjerte- og karsykdommer introduseres en trinnvis tiltaksmodell.
- Open Access
- 20 July 2022
- Published by Elsevier in Sleep Medicine
- Vol. 100, S144-S145
Worry, rumination and insomnia in patients with coronary heart disease -a cross-sectional study with long-term follow-up
- 20 July 2022
- Published by Elsevier in Sleep Medicine
- Vol. 100, S144-S145
Open AccessWorry, rumination and insomnia in patients with coronary heart disease -a cross-sectional study with long-term follow-up
- 1 February 2022
- Published by Wiley in Journal of Internal Medicine
- Vol. 291 (6) , 891-893
Tailored clinical management after blinded statin challenge improved the lipid control in coronary patients with self‐perceived muscle side effects
- 1 February 2022
- Published by Wiley in Journal of Internal Medicine
- Vol. 291 (6) , 891-893
Tailored clinical management after blinded statin challenge improved the lipid control in coronary patients with self‐perceived muscle side effects
- Open Access
- 1 January 2022
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 3 (1) , zpac007
Insomnia as a predictor of recurrent cardiovascular events in patients with coronary heart disease
Study Objectives: Insomnia is highly prevalent in patients with coronary heart disease (CHD). However, the potential effect of insomnia on the risk of recurrent major adverse cardiovascular events (MACE) remains uncertain.Methods: This prospective cohort study included 1082 consecutive patients 2–36 (mean 16) months after myocardial infarction and/or coronary revascularization. Data on clinical insomnia, coronary risk factors, and comorbidity were collected at baseline. Clinical insomnia was assessed using the Bergen Insomnia Scale (BIS). The primary composite endpoint of MACE (cardiovascular death, hospitalization due to myocardial infarction, revascularization, stroke, or heart failure) was assessed with an average follow-up of 4.2 (SD 0.3) years after baseline. Data were analyzed using Cox proportional hazard regression models stratified by prior coronary events before the index event.Results: At baseline, mean age was 62 years, 21% were females, and 45% reported clinical insomnia. A total of 346 MACE occurred in 225 patients during the follow-up period. For clinical insomnia, the relative risk of recurrent MACE was 1.62 (95% confidence interval [CI]: 1.24–2.11, p < .001) adjusted for age, gender, and previous coronary events. In a multi-adjusted analysis, including coronary risk factors, cardiovascular comorbidity, symptoms of anxiety, and depression, the relative risk was 1.41 (95% CI: 1.05–1.89, p = .023). Clinical insomnia accounted for 16% of the MACE in attributable risk fraction analyses, being third in importance after smoking (27%) and low physical activity (21%).Conclusions: Clinical insomnia was associated with increased risk of recurrent MACE. These results emphasize the importance of identifying and managing insomnia in CHD outpatients.
- 1 January 2022
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 3 (1) , zpac007
Open AccessInsomnia as a predictor of recurrent cardiovascular events in patients with coronary heart disease
Study Objectives: Insomnia is highly prevalent in patients with coronary heart disease (CHD). However, the potential effect of insomnia on the risk of recurrent major adverse cardiovascular events (MACE) remains uncertain.Methods: This prospective cohort study included 1082 consecutive patients 2–36 (mean 16) months after myocardial infarction and/or coronary revascularization. Data on clinical insomnia, coronary risk factors, and comorbidity were collected at baseline. Clinical insomnia was assessed using the Bergen Insomnia Scale (BIS). The primary composite endpoint of MACE (cardiovascular death, hospitalization due to myocardial infarction, revascularization, stroke, or heart failure) was assessed with an average follow-up of 4.2 (SD 0.3) years after baseline. Data were analyzed using Cox proportional hazard regression models stratified by prior coronary events before the index event.Results: At baseline, mean age was 62 years, 21% were females, and 45% reported clinical insomnia. A total of 346 MACE occurred in 225 patients during the follow-up period. For clinical insomnia, the relative risk of recurrent MACE was 1.62 (95% confidence interval [CI]: 1.24–2.11, p < .001) adjusted for age, gender, and previous coronary events. In a multi-adjusted analysis, including coronary risk factors, cardiovascular comorbidity, symptoms of anxiety, and depression, the relative risk was 1.41 (95% CI: 1.05–1.89, p = .023). Clinical insomnia accounted for 16% of the MACE in attributable risk fraction analyses, being third in importance after smoking (27%) and low physical activity (21%).Conclusions: Clinical insomnia was associated with increased risk of recurrent MACE. These results emphasize the importance of identifying and managing insomnia in CHD outpatients.
- Open Access
- 1 November 2021
- Published by Elsevier in Atherosclerosis
- Vol. 336, 23-29
The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease
- 1 November 2021
- Published by Elsevier in Atherosclerosis
- Vol. 336, 23-29
Open AccessThe relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease